Secondary Care - Prescribing Lifestyle Adjustments for Cardiovascular Health (Phase II)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- University of South Wales
- Enrollment
- 38
- Locations
- 1
- Primary Endpoint
- A prescription (LRx) being issued during a consultation
Study Overview
Brief Summary
Prescribing lifestyle changes to patients who have cardiovascular disease (CVD) may be an extremely cost effective mechanism of improving health individually and for the NHS. Positive lifestyle changes such as improved diet, increased physical activity, quitting smoking and reducing alcohol consumption have been proven to reform the health status of individuals with CVD. S-PLAC 2 is a phase II study to determine the efficacy of a lifestyle prescription (L℞) in patients and healthcare practitioners in a secondary care setting (i.e. hospital clinics/wards).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18 and over
- •Able and willing to provide written informed consent
- •Understands written and spoken English
- •Either an in/out- patient of Cardiology
Exclusion Criteria
- •Participant is unwilling or unable to provide written informed consent
- •Participant is pregnant
- •Participant has a drug dependency
Outcomes
Primary Outcomes
A prescription (LRx) being issued during a consultation
Time Frame: During month 7 of the study
Number of so-signed prescription (LRx) forms. Total number of forms to be co-signed = 60
Patient view of the prescription (LRx) and consultation Questionnaire
Time Frame: During month 7 of the study
Completed study questionnaires. Total number of questionnaires to be completed = 120. Responses will be recorded to gain feedback from the patient participants regarding their thoughts and feelings of their consultation with and without the intervention of the prescription (LRx). Scale: 7 (minimum) to 41 (maximum). A lower value represents a better (more positive) outcome.
Healthcare practitioner (HCP) view of the prescription (LRx) and consultation questionnaire.
Time Frame: During month 7 of the study
Completed clinician questionnaire. Total number of questionnaires to be completed = 6. Responses will be recorded to gain feedback from the clinicians regarding their thoughts and feelings of their consultations with and without the intervention of the prescription (LRx). Sections: Section 1 scale: 9 to 54 (a lower score represents a better, more positive outcome) Section 2 scale: 8 to 48 (a lower score represents a better, more positive outcome) Section 3 scale: 6 to 36 (a lower score represents a better, more positive outcome) Total score available: 23 to 138
Secondary Outcomes
No secondary outcomes reported